Letter: clarithromycin dose for H. pylori therapy remains unresolved

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|42|5|631-632

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.42, Iss.5, 2015-09, pp. : 631-632

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Letter: clarithromycin dose for H. pylori therapy remains unresolved – authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 5, 2015-09 ,pp. : 632-633

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 7, 2015-10 ,pp. : 942-943

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm – author's reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 7, 2015-10 ,pp. : 943-944

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review and meta‐analysis: full‐ vs. half‐dose anti‐microbials in clarithromycin‐based regimens for Helicobacter pylori eradication

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 2, 2015-07 ,pp. : 131-141

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: quadruple therapy for H. pylori eradication is better than triple therapy

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 7, 2015-04 ,pp. : 694-695

John Wiley & Sons Inc

Access to resources Recommend Favorite